Vitamin D supplementation and disease activity in patients with immune-mediated rheumatic diseases

Medicine (United States)

Volumn 96, Issue 23, 2017, Pages

  Franco, André Silva ^a   Freitas, Thiago Quadrante ^a   Bernardo, Wanderley M ^b   Pereira, Rosa Maria R ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Brazilian Medical Association Evidence Based Guidelines Developing   (Brazil)

Author keywords

disease activity; meta analysis; rheumatic diseases; rheumatoid arthritis; systemic lupus erythematosus; Vitamin D

Indexed keywords

ALFACALCIDOL; CALCITRIOL; CHLOROQUINE; COLECALCIFEROL; DOUBLE STRANDED DNA ANTIBODY; ERGOCALCIFEROL; GLUCOCORTICOID; METHOTREXATE; PLACEBO; VITAMIN D;

ARTICLE; CINAHL; CLINICAL OUTCOME; COCHRANE LIBRARY; DAS28; DISEASE ACTIVITY; EMBASE; HUMAN; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RHEUMATOID ARTHRITIS; RISK REDUCTION; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; VISUAL ANALOG SCALE; VITAMIN SUPPLEMENTATION; DIET THERAPY; DIETARY SUPPLEMENT; RHEUMATIC DISEASE;

DIETARY SUPPLEMENTS; HUMANS; RHEUMATIC DISEASES; VITAMIN D;

EID: 85020413306     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000007024     Document Type: Article

References (58)

1. Pelajo CF, Lopez-Benitez JM, Miller LC. Vitamin D and autoimmune rheumatologic disorders. Autoimmun Rev 2010; 9: 507-10
2. Holick MF. Vitamin D: a millenium perspective. J Cell Biochem 2003; 88: 296-307
3. Christakos S, Dhawan P, Verstuyf A, et al. Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects. Physiol Rev 2016; 96: 365-408
4. Kamen D, Aranow C. Vitamin D in systemic lupus erythematosus. Curr Opin Rheumatol 2010; 20: 532-7
5. Rossini M, Maddali Bongi S, La Montagna G, et al. Vitamin D deficiency in rheumatoid arthritis: prevalence, determinants and associations with disease activity and disability. Arthritis Res Ther 2010; 12: 1-7
6. Eloi M, Horvath DV, Ortega JC, et al. 25-Hydroxivitamin D serum concentration, not free and bioavailable vitamin D, is associated with disease activity in systemic lupus erythematosus patients. PLoS One 2017; 12: e0170323
7. Jeffery LE, Raza K, Hewison M. Vitamin D in rheumatoid arthritistowards clinical application. Nat Rev Rheumatol 2015; 12: 201-10
8. Rook GA, Steele J, Fraher L, et al. Vitamin D3, gamma interferon, and control of proliferation of Mycobacterium tuberculosis by human monocytes. Immunology 1986; 57: 159-63
9. Stumpf W, Sar M, Reid F, et al. Target cells for 1, 25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science 1979; 206: 1188-90
10. Adams JS, Hewison M. Extrarenal expression of the 25-hydroxyvitamin D-1-hydroxylase. Arch Biochem Biophys 2012; 523: 95-102
11. Gatenby P, Lucas R, Swaminathan A. Vitamin D deficiency and risk for rheumatic diseases: an update. Curr Opin Rheumatol 2017; 25: 184-91
12. Marinho A, Taveira M, Vasconcelos C. Topics on vitamin D in systemic lupus erythematosus: analysis of evidence and critical literature review. Immunol Res 2017; 65: 495-511
13. He XJ, Ding Y, Xiang W, et al. Roles of 1, 25(OH)2D3 and vitamin D receptor in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus by regulating the activation of CD4 + T cells and the PKCd /ERK signaling pathway. Physiology C 2017; 40: 743-56
14. Vasile M, Corinaldesi C, Antinozzi C, et al. Vitamin D in autoimmune rheumatic diseases: a view inside gender differences. Pharmacol Res 2016; 117: 228-41
15. Cantorna MT. Mechanisms underlying the effect of vitamin D on the immune system. Proc Nutr Soc 2010; 69: 286-9
16. Baeke F, Takiishi T, Korf H, et al. Vitamin D: modulator of the immune system. Curr Opin Pharmacol 2010; 10: 482-96
17. Lemire JM, Adams JS, Kermani-Arab V, et al. 1, 25-Dihydroxyvitamin D3 suppresses human T helper/inducer lymphocyte activity in vitro. J Immunol 1985; 134: 3032-5
18. Mahon BD, Wittke A, Weaver V, et al. The targets of vitamin D depend on the differentiation and activation status of CD4 positive T cells. J Cell Biochem 2003; 89: 922-32
19. Joshi S, Pantalena L-C, Liu XK, et al. 1, 25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. Mol Cell Biol 2011; 31: 3653-69
20. Unger WWJ, Laban S, Kleijwegt FS, et al. Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1. Eur J Immunol 2009; 39: 3147-59
21. Garrett-Sinha LA, John S, Gaffen SL. IL-17 and the Th17 lineage in systemic lupus erythematosus. Curr Opin Rheumatol 2008; 20: 519-25
22. Hsu H-C, Yang P, Wang J, et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol 2008; 9: 166-75
23. Matusevicius D, Kivisäkk P, He B, et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999; 5: 101-4
24. Cantorna MT, Hayes CE, DeLuca HF. 1, 25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci U S A 1996; 93: 7861-4
25. Ding Y, Liao W, He X-J, et al. Effects of 1, 25(OH)2 D3 and vitamin D receptor on peripheral CD4+/CD8+ double-positive T lymphocytes in a mouse model of systemic lupus erythematosus. J Cell Mol Med 2016; 21: 975-85
26. Lemire JM, Ince A, Takashima M. 1, 25-Dihydroxyvitamin D3 attenuates the expression of experimental murine lupus of MRL/l mice. Autoimmunity 1992; 12: 143-8
27. Cranney A, Horsley T, O'Donnell S, et al. Effectiveness and safety of vitamin D in relation to bone health. Evid Rep Technol Assess (Full Rep) 2007; 158: 1-235
28. Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006; 354: 669-83
29. Abrahamsen B, Sahota O. Do calcium plus vitamin D supplements increase cardiovascular risk?. BMJ 2011; 342: d2080
30. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010; 62: 1515-26
31. Pereira RMR, de Carvalho JF, Paula AP, et al. Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis. Rev Bras Reumatol 2012; 52: 580-93
32. Tang BMP, Eslick GD, Nowson C, et al. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet (London, England) 2007; 370: 657-66
33. Abrahamsen B, Harvey NC. The role of vitamin D supplementation in patients with rheumatic diseases. Nat Rev Rheumatol 2013; 9: 411-22
34. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008; 58: 15-25
35. Radner H, Yoshida K, Smolen JS, et al. Multimorbidity and rheumatic conditions-enhancing the concept of comorbidity. Nat Rev Rheumatol 2014; 10: 252-6
36. Marsico A, Atzeni F, Piroddi A, et al. Costs of pain in rheumatology. Reumatismo 2014; 66: 103-7
37. Péntek M, Poór G, Wiland P, et al. Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries. Eur J Health Econ 2014; 15(suppl 1): S35-43
38. Dehghan A, Rahimpour S, Soleymani-Salehabadi H, et al. Role of vitamin D in flare ups of rheumatoid arthritis. Z Rheumatol 2014; 73: 461-4
39. Gopinath K, Danda D. Supplementation of 1, 25 dihydroxy vitamin D3 in patients with treatment naive early rheumatoid arthritis: A randomised controlled trial. Int J Rheum Dis 2011; 14: 332-9
40. Hansen KE, Bartels CM, Gangnon RE, et al. An evaluation of high-dose vitamin D for rheumatoid arthritis. J Clin Rheumatol 2014; 20: 112-4
41. Salesi M, Farajzadegan Z. Efficacy of Vitamin D in patients with active rheumatoid arthritis receiving methotrexate therapy. Rheumatol Int 2012; 32: 2129-33
42. Yang J, Liu L, Zhang Q, et al. Effect of vitamin D on the recurrence rate of rheumatoid arthritis. Exp Ther Med 2015; 10: 1812-6
43. Abou-Raya A, Abou-Raya S, Helmii M. The effect of vitamin D supplementation on inflammatory and hemostatic markers and disease activity in patients with systemic lupus erythematosus: a randomized placebo-controlled trial. J Rheumatol 2013; 40: 265-72
44. Aranow C, Kamen DL, Dall'Era M, et al. Randomized, double-blind, placebo-controlled trial of the effect of vitamin D3 on the interferon signature in patients with systemic lupus erythematosus. Arthritis Rheumatol (Hoboken, NJ) 2015; 67: 1848-57
45. Lima GL, Paupitz J, Aikawa NE, et al. Vitamin D supplementation in adolescents and young adults with juvenile systemic lupus erythematosus for improvement in disease activity and fatigue scores: a randomized, double-blind, placebo-controlled trial. Arthritis Care Res (Hoboken) 2016; 68: 91-8
46. Hulshof MM, Bavinck JNB, Bergman W, et al. Double-blind, placebocontrolled study of oral calcitriol for the treatment of localized and systemic scleroderma. J Am Acad Dermatol 2000; 43: 1017-23
47. Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health. Available at: www.OpenEpi.com. Accessed January 1 2015
48. The Nordic Cochrane Centre TCC. Review Manager (RevMan 2014
49. Tetlow LC, Woolley DE. The effects of 1 alpha, 25-dihydroxyvitamin D (3) on matrix metalloproteinase and prostaglandin E(2) production by cells of the rheumatoid lesion. Arthritis Res 1999; 1: 63-70
50. Lin J, Liu J, Davies ML, et al. Serum Vitamin D level and rheumatoid arthritis disease activity: review and meta-analysis. PLoS One 2016; 11: 1-7
51. Shahin D, El-farahaty RM, Houssen ME, et al. Serum 25-OH vitamin D level in treatment-naive systemic lupus erythematosus patients: Relation to disease activity. IL-23 and IL-17 2016; 23: 1-0
52. Ritterhouse LL, Crowe SR, Niewold TB, et al. Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus. Ann Rheum Dis 2011; 70: 1569-74
53. Petri MA, Van Vollenhoven RF, Buyon J, et al. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. Arthritis Rheum 2013; 65: 2143-53
54. Petri M, Singh S, Tesfasyone H, et al. Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: a prospective study. J Rheumatol 2009; 36: 2476-80
55. Nikpour M, Urowitz MB, Ibañez D, et al. Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Care Res 2009; 61: 1152-8
56. Durcan L, Petri M. Immunomodulators in SLE: clinical evidence and immunologic actions. J Autoimmun 2016; 74: 73-84
57. Floris A, Piga M, Cauli A, et al. Predictors of flares in Systemic Lupus Erythematosus: preventive therapeutic intervention based on serial antidsDNA antibodies assessment. Analysis of a monocentric cohort and literature review. Autoimmun Rev 2016; 15: 656-63
58. Pan N, Amigues I, Lyman S, et al. A surge in anti-dsDNA titer predicts a severe lupus flare within six months. Lupus 2014; 23: 293-8